Chemotherapy-induced Nausea and Vomiting Drugs Market Size , Share , Analysis and Forecasts To 2021
Market Research Analysts forecast the global CINV drugs market to grow at a CAGR of 5.41 % during the period 2017-2021 .
According to the report , the high unmet medical need in the market has driven the R & D activities of existing as well as new vendors . Helsinn is one of the leading companies that has a strong pipeline of CINV drugs with two drug candidates in Phase III and Phase I stages . Helsinn has collaborated with Taiho Pharmaceutical for the development and commercialization of netupitant IV in Japan . Heron Therapeutics is developing HTX-019 , currently in Phase I stage , for the prevention and treatment of CINV . In addition , new vendors such as Shin Nippon Biomedical Laboratories and Acacia Pharma are aggressively advancing their pipeline to launch new drugs during the forecast period . Shin Nippon Biomedical Laboratories and Acacia are developing granisetron intranasal and APD403 , respectively . Both these drugs are in Phase II development stage . These pipeline drugs are expected to gain approval during the forecast period and will likely fuel the market growth .
Download Sample Report @ https :// marketreportscenter . com / request-sample / 494138
Covered in this report
The report covers the present scenario and the growth prospects of the global CINV drugs market for 2017-2021 . To calculate the market size , the report considers the revenue generated from the sales of CINV drugs .
The market is divided into the following segments based on geography :
Americas APAC EMEA
Technavio ' s report , Global Thoracic Surgery Market 2017-2021 , has been prepared based on an in-depth market analysis with inputs from industry experts . The report covers the market landscape and its growth prospects over the coming years . The report also includes a discussion of the key vendors operating in this market .
Key vendors GlaxoSmithKline Helsinn Heron Therapeutics Merck Tesaro